Ahmad M Mansour1, Iqbal Ike K Ahmed2, Brennan Eadie2, Elias Chelala3, Joanna S Saade4, Stephen G Slade5, Ali A Mearza6, Dipak Parmar7, Marwan Ghabra7, Sheila Luk8, Alla Kelly9, Stephen C Kaufman10. 1. Department of Ophthalmology, American University of Beirut, Beirut, Lebanon Department of Ophthalmology, Rafic Hariri University Hospital, Beirut, Lebanon. 2. Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada. 3. Department of Ophthalmology, Hotel Dieu de France, Beirut, Lebanon. 4. Department of Ophthalmology, American University of Beirut, Beirut, Lebanon. 5. The Laser Center, Houston, Texas, USA. 6. Department of Ophthalmology, Imperial College, London, UK. 7. Department of Ophthalmology, Whipps Cross University Hospital, London, UK. 8. Department of Ophthalmology, Western Eye Hospital, London, UK. 9. Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA. 10. Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA Department of Ophthalmology, State University of New York Downstate, Brooklyn, New York, USA.
Abstract
PURPOSE: NewColorIris cosmetic iris implants have a record of high ocular morbidity and are no longer in use. Newer generation of iris implants, BrightOcular, have patented posterior grooves in order to decrease iris touch and facilitate aqueous flow around the implant. However, little is known about their safety despite their implantations in 10 countries. METHODS: Collaborative case series of patients who had bilateral implantation of cosmetic iris implants solely for cosmetic reasons. RESULTS: 12 cases were collected being distributed as Caucasian (10) and Asian (2), women (11) and man (1) and with a mean age of 32 years. Ocular manifestations were present in 11 subjects and included anterior uveitis (10 of 12; 83.3%), glaucoma (7 of 12; 58.3%) and corneal decompensation (6 of 12; 50%). Visual acuity was normal in seven, decreased in five with two having visual recovery following explantation of the implant. Glaucoma could not be controlled medically in two patients. CONCLUSIONS: Cosmetic iris implants carry the risk of ocular damage when implanted in the anterior chamber of normal phakic eyes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
PURPOSE: NewColorIris cosmetic iris implants have a record of high ocular morbidity and are no longer in use. Newer generation of iris implants, BrightOcular, have patented posterior grooves in order to decrease iris touch and facilitate aqueous flow around the implant. However, little is known about their safety despite their implantations in 10 countries. METHODS: Collaborative case series of patients who had bilateral implantation of cosmetic iris implants solely for cosmetic reasons. RESULTS: 12 cases were collected being distributed as Caucasian (10) and Asian (2), women (11) and man (1) and with a mean age of 32 years. Ocular manifestations were present in 11 subjects and included anterior uveitis (10 of 12; 83.3%), glaucoma (7 of 12; 58.3%) and corneal decompensation (6 of 12; 50%). Visual acuity was normal in seven, decreased in five with two having visual recovery following explantation of the implant. Glaucoma could not be controlled medically in two patients. CONCLUSIONS: Cosmetic iris implants carry the risk of ocular damage when implanted in the anterior chamber of normal phakic eyes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Christian S Mayer; Andrea E Laubichler; Ramin Khoramnia; Tamer Tandogan; Philipp Prahs; Daniel Zapp; Lukas Reznicek Journal: J Ophthalmol Date: 2018-09-23 Impact factor: 1.909